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Background: Variation in survival in hepatocellular carcinoma (HCC) has been attributed to different aetiologies or disease stages
at presentation. While international guidelines recommend surveillance of high-risk groups to permit early diagnosis and curative
treatment, the evidence that surveillance decreases disease-specific mortality is weak.
Methods: We compared HCC survival figures from Japan (n¼ 1174) and Hong Kong (n¼ 1675) over similar time periods (Japan
2000–2013, Hong Kong, China 2003–2014). The former has an intensive national surveillance programme, while the latter has none.
We also analysed changes in survival in Japan over a 50-year period including data from before and after institution of a national
HCC surveillance programme.
Results: In Japan, over 75% of cases are currently detected by surveillance, whereas in Hong Kong o20% of cases are detected
presymptomatically. Median survival was 52 months in Japan and 17.8 months in Hong Kong; this survival advantage persisted after
allowance for lead-time bias. Sixty-two per cent of Japanese patients had early disease at diagnosis and 63% received curative treatment.
The comparable figures for Hong Kong were 31.7% and 44.1%, respectively. These differences could not be accounted for by disease
aetiology, and patients in Hong Kong who were detected at an early stage had a similar survival to the analogous patients in Japan.
Conclusions: The variation in survival is largely accounted for by stage at diagnosis, which in turn relates to the intensity of
surveillance programmes and the consequent variation in curative therapeutic options.
A striking feature of hepatocellular carcinoma (HCC) is the wide
global variation in incidence, ranging from o3/100 000 in
Northern Europe to 430/100 000 in parts of Africa and China
(Parkin et al, 2005). In all regions, most HCC arises in the setting
of chronic liver disease (Llovet, 2005). Equally striking is the wide
variation in reported median survival figures ranging from o3
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months in parts of Africa to43 years in Taiwan and Japan (Chen
et al, 2006; Hsu et al, 2010).
Recognising the crucial importance of early diagnosis for the
implementation of potentially curative therapy, most international
guidelines suggest that patients at high HCC risk (Omata et al,
2010; Bruix and Sherman, 2011; For Research, EO and Liver,
EAFTSOT, 2012; Song et al, 2012) are screened by six monthly
ultrasound (US) examinations with or without the serum tumour
marker a-fetoprotein (AFP). However, systematic reviews conclude
that the evidence that surveillance decreases disease-specific
mortality is weak (Kansagara et al, 2014) and the US National
Cancer Institute concludes that ‘surveillance of persons at elevated
risk does not result in a decrease in mortality from hepatocellular
cancer’ (NCI). The only randomised trial showing benefit from
surveillance (Zhang et al, 2004) had significant methodological
limitations (Kansagara et al, 2014). Furthermore, although those
who are detected within a surveillance programme tend to have
‘earlier’ disease and survive longer, the possibility that this is
attributable to lead-time bias is difficult to exclude (Singal et al,
2014; Sherman, 2014b). However, it is recognised that a formal
randomised trial of surveillance to provide the relevant evidence
base is now impossible, not least because properly informed
patients would not consent to recruitment to a control, unscreened
arm, particularly in the light of international clinical guidelines
(McCaughan, 2013; Kansagara et al, 2014; Singal et al, 2014;
Sherman, 2014b). On the basis of this lack of evidence, most
Western countries have chosen not to implement a national
surveillance programme and it has been left to individual hospitals
or clinicians to undertake surveillance resulting in very variable
practice (Dalton-Fitzgerald et al, 2014; Joshi et al, 2014). Thus,
patients are caught between guidelines written by HCC ‘experts’
who strongly support surveillance and funders who are reluctant to
act on these guidelines in the absence of a firm conventional
evidence base, while both sides recognise that such an evidence
base is impossible to acquire.
In an attempt to provide some evidence as to the potential
benefits of surveillance for HCC without a formal randomised trial,
we have compared HCC survival rates in two national patient
cohorts both with advanced and sophisticated health-care systems.
One of these, Japan, has a mature, intensive, national programme
of surveillance for HCC, whereas the second, Hong Kong, has not
introduced such a programme.
PATIENTS AND METHODS
The study involved patient level data from HCC centres in Japan
and Hong Kong, China. Part of the Japan cohort has previously
been reported by Toyoda et al (2006b), whereas the Chinese cohort
comprised consecutive patients drawn from the North West
Territories, Hong Kong. We also had access to historical data
pertaining to changes occurring in the same region of Japan over
the period between 1969 and 2013 in terms of age, survival, 90-day
postoperative mortality, tumour size and stage (as assessed by the
Japanese Integrated Staging (JIS) score) with which to assess the
impact of the introduction of surveillance in 1980.
Diagnosis, tumour characteristics and assessment of survival.
Patients were diagnosed on the basis of characteristic radiology
according to international guidelines (For Research, EO and Liver,
EAFTSOT, 2012) or histological examination of tumour tissue.
Survival was calculated from date of diagnosis. Parameters
recorded common to both cohorts are shown in Table 1. Aetiology
was classified as hepatitis B virus (HBV) or hepatitis C virus
(HCV) related or ‘other’, the latter including alcoholic and other
forms of chronic liver disease (Table 1). Where aetiology was
mixed, typically HCV and alcohol, the former was recorded.
Treatment and staging. Japanese patients were staged according
to the JIS score (Kudo et al, 2003). In Hong Kong (China),
treatment was decided in multidisciplinary meetings. Liver
transplantation was not available in the Hong Kong or Japanese
centres. Both units had ready access to ‘state-of-the-art’ treatments,
which was not influenced by cost considerations. The Milan
Criteria (three tumourso3 cm or one tumouro5 cm; Mazzaferro
et al, 1996) was used to classify patients as having early (potentially
curative disease) or advanced disease (Singal et al, 2014). Resection,
radiofrequency ablation and percutaneous ethanol injection were
considered potentially curative treatments. All other treatment
options were considered palliative.
Surveillance policy. Mass surveillance was introduced in Japan in
1980. The approach adopted in the Ogaki prefecture, described
here, is typical of the whole of Japan (The Japan Society of
Hepatology, 2010a, b; Kudo et al, 2016). The population above the
age of 50 years is offered regular screening for chronic viral
hepatitis. All patients with cirrhosis or severe fibrosis are followed-
up with US examination every 3–6 months; no patients are
excluded on the grounds of advanced liver disease/liver failure.
Regular monitoring of tumour markers (AFP, AFP-L3% and des-
gamma-carboxy prothrombin) is also performed every 3–6
months. When an increase of tumour markers is observed,
additional imaging examinations are performed. In Hong Kong,
China there was no formal surveillance programme.
Statistical methods. Statistical analysis was undertaken using
Stata IC 12 (Stata Corp, College Station, TX, USA). Survival curves
were generated by the Kaplan–Meier method. Univariable Cox
regression analysis was used to identify significant prognostic
variables in each of the cohorts. Variables analysed were age,
gender, albumin (g l 1), AFP (ngml 1), bilirubin (mmol l 1),
treatment (curative/palliative), tumour size (cm), tumour type
(solitary or multifocal), vascular invasion, aetiology (HCV/HBV/
HCVþHBV, other) and screening status. A log transformation
was made to AFP and bilirubin because of extreme skewness. To
make allowance for lead-time bias introduced by systematic
surveillance, we applied the method of Duffy et al (2008). Using
forward selection, a multivariable Cox proportional hazards model
was built to explain variation in survival as related to clinical
features and aetiological factors.
RESULTS
Comparing similar time periods (Japan 2000–2013; Hong Kong,
China 2003–2014), median survival in Japan was 52 months
compared with 17.8 months in Hong Kong (Figure 1A). This
difference in survival was maintained even after allowing for lead-
time bias (Figure 1B). By all measures of disease extent and stage
(tumour sizeo3 cm, multifocality, vascular invasion as well as the
Milan Criteria), the Japanese cohort had much earlier disease at
diagnosis (Table 2). However, within that cohort of Hong Kong
patients who were detected at an early stage (i.e., within the Milan
Criteria), the median survival was actually significantly better than
for the analogous Japanese group (Figure 1C), although among
those with good liver function (Child–Pugh grade ‘A’) survival
figures were virtually identical (Figure 1D) as were results among
those who underwent surgical resection or who were classified as
receiving curative theory (data not shown). Comparing the
Kaplan–Meier survival curves for late-stage patients with tumour
sizes of over 5 cm (outside the Milan criteria) showed that there
was no statistically significant difference (P¼ 0.2068) between the
Japanese and Chinese patients (Supplementary Figure 1).
Changes in survival following introduction of surveillance
programme in Japan. In the latest cohort (2000–2013), 78% of
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Japanese HCC cases were detected by surveillance. The high
current median survival seen in Japan was preceded by increasing
survival rates over several decades (Figure 1E). Thus, between the
years of 1966 and 1980 when there was no surveillance programme
in place, median survival in Japan was o3 months (Toyoda et al,
2006a). Survival improved over each following decade, from 8.8
months between 1980 and 1989 to the most recent figure of over 4
years (2000–2013; Figure 1E). The median age at diagnosis also
increased each decade, from 60.5 years before the initiation of a
surveillance programme to 70 years during the most recent analysis
period (Table 3). In parallel with these changes, there was a shift
towards earlier disease stage with the proportion of patients with
stage 0/1 (the earliest stages according to the JIS), rising from 3.4%
between 1966 and 1979 to 53.4% between 2000 and 2013 (Table 3).
In the Japanese data set, a clear distinction had been recorded
between those detected within the formal surveillance programme
and the remaining ‘unscreened’ patients. Those who were screened
had an earlier disease stage compared with those who were
unscreened. For example, percentages for receiving curative
treatment, within the Milan Criteria, tumour sizes o3 cm,
multifocality and vascular invasion were 40.6%, 27.7%, 22.3%,
62.5% and 41.7%, respectively, for those who were unscreened
compared with 69.1%, 71.8%, 61.5%, 38.4% and 8.7%, respectively,
for screened patients. We therefore applied the previously
referenced statistical method to assess the contribution of lead-
and length-time bias to this cohort. This showed that the difference
between the screened and unscreened cohorts decreased from 46.3
to 19.8 months but remained highly significant (Po0.0001;
Figure 1F and Supplementary Figure 2). Median survival in other
subgroups are summarised in Table 3.
Role of aetiology and surveillance in HCC survival. Direct
comparison between Japan and Hong Kong is complicated by
major differences in aetiology, with Japanese patients being
predominately HCV related and Hong Kong patients HBV related.
Despite this in both aetiologies, patients in Japan clearly survived
longer than those in Hong Kong (Supplementary Figures 3a and b)
and multivariable analysis (Table 4) showed that tumour-related
factors, such as vascular invasion, AFP and tumour size, but not
aetiology, accounted for these differences (Supplementary Tables 1
and 2). When disease stage factors are accounted for in a
multivariable Cox regression analysis, screening status variable
becomes insignificant (P40.05), indicating that any differences in
survival between the two groups (screened and unscreened) is
accounted for by disease stage. All univariable analysis is shown in
Supplementary Tables 3 and 4.
DISCUSSION
The stage of HCC at presentation was the most important factor
influencing survival. Patients with early-stage disease are more
likely to receive potentially curative therapy and survive longer.
When we applied a statistical method that adjusts for lead and
length-time bias, significant benefit remained among the screened
population in Japan (log-rank test, Po0.0001). This method has
limitations in that it is not specific for HCC but other approaches
that make allowance for lead-time bias, using HCC-specific
features, have arrived at similar conclusions. Specifically Mourad
et al (2014), found the same using a modelling approach and
Table 1. Characteristics of the cohorts
Japan Hong Kong, China
N 2605 1675
Accrual period 1966–1999, n¼1431 2000–2013, n¼1174 2003–2014
% Ethnicity 495% (Oriental) 495% (Oriental) 495% (Oriental)
Age (years)
Median (IQR) 63 (56, 69) 70 (63, 76) 59 (52, 68)
Mean (±s.d.) 62.6 (±9.5) 68.8 (±9.5) 59.6 (±11.4)
% Male 75.8, n¼1431 70.8, n¼1174 84.6, n¼1675
% Aetiology n¼1326 n¼1174 n¼1112
HCV 48.8 66.4 6.7
HBV 21.6 15.7 80.5
HCVþHBV 0.9 0.9 0.5
Othera 28.7 17 12.2
Liver function and cancer biomarkers
AFP (ngml1), median (IQR) 68.0 (14, 1130), n¼ 1216 21.3 (6.3, 208.5), n¼1156 107 (9, 2869), n¼1675
Bilirubin (mmol l1), median (IQR) 17.1 (10.3, 29.1), n¼ 1404 13.7 (10.3, 22.2), n¼1168 15 (10, 26), n¼1675
Albumin (g l 1), median (IQR) 32 (27, 36), n¼ 1375 36 (32, 40), n¼ 1168 38 (34, 42), n¼1675
% Child score (A : B : C) 46.0 : 39.1 : 15.0, n¼ 1429 70.2 : 22.5 : 7.3, n¼1174 75.9 : 20.2 : 3.9, n¼1675
Tumour characteristics and disease stage
% Multifocal 67.4, n¼1431 43.8, n¼1165 45.4, n¼1675
Tumour size n¼1043 n¼1164 n¼1600
o3 cm (%) 44.9 52.8 25.3
3–5 cm (%) 27.1 22.3 25.6
5.1–10 cm (%) 20.9 18.9 25.9
410 cm (%) 7.1 6 23.2
% Vascular invasion (presence) 42.4, n¼1341 16, n¼1163 26.7, n¼1675
% HCC detected through surveillance 59.50, n¼1312 77.60, n¼1172 NA
% within the Milan Criteria 35.2, n¼1430 62, n¼1159 31.7, n¼1624
Treatment (% curative) 29.3, n¼1431 62.8, n¼1170 44.1, n¼1675
Survival
Median overall survival (months) 16.6, n¼1430 52, n¼1174 17.8, n¼1672
Abbreviations: AFP¼ a-fetoprotein; HBV¼ hepatitis B virus; HCC¼hepatocellular carcinoma; HCV¼ hepatitis C virus; IQR¼ interquartile range; NA¼ not applicable.
aOther aetiology includes alcoholic, fatty liver disease, haemochromatosis, autoimmune hepatitis and cryptogenic.
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Figure 1. Kaplan–Meier curves showing survival. (A) In the Japanese and Chinese cohorts, (B) in the Japanese and Chinese cohorts after lead-time
bias, (C) in Japanese and Chinese patients who were within the Milan criteria, (D) in Japanese and Chinese patients who were within the Milan
Criteria and Child–Pugh A, (E) in Japan over the decades (1966–1979, 1980–1989, 1990–1999 and 2000–2013) and (F) survival according to
screening status (after lead-time bias adjustment) in the Japanese (and Chinese) cohorts.
Table 2. Percentage of patients with curative treatments, early-stage BCLC and within the Milan Criteria
Cohort % screened % curative
% within Milan
Criteria
% tumour size
o3 cm % multifocal
% vascular
invasion
Japan 1966–1979 12.9 (n¼ 132) 3.3 (n¼150) 6.0 (n¼ 149) 12.5 (n¼ 16) 93.3 (n¼150) 86.3 (n¼73)
Japan 1980–1989 53.1 (n¼ 375) 16.2 (n¼476) 20.0 (n¼ 476) 30.2 (n¼ 291) 75.2 (n¼476) 62.9 (n¼464)
Japan 1990–1999 70.1 (n¼ 805) 41.9 (n¼805) 50.1 (n¼ 805) 51.4 (n¼ 736) 57.9 (n¼805) 26.6 (n¼804)
Japan 2000–2013 77.6 (n¼ 1172) 62.8* (n¼1170) 62.0* (n¼ 1159) 52.8* (n¼ 1164) 43.8** (n¼1165) 16.0* (n¼1163)
Hong Kong NA 44.1* (n¼1675) 31.7* (n¼ 1624) 25.3* (n¼ 1600) 45.4** (n¼1675) 26.7* (n¼1675)
Abbreviation: BCLC¼Barcelona-Clinic Liver Cancer. Note: Comparing Japan (2000–2013) and Hong Kong, China. *Po0.0001 and **P¼ 0.4.
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Cucchetti et al (2014) concluded that even after lead-time bias
adjustment, semiannual surveillance maintained a survival benefit
over symptomatic diagnosis. The fact that the median age at
diagnosis in Japan has not fallen since the surveillance programme
was initiated, but rather increased, may offer further evidence that
lead-time bias does not account for all the benefit of surveillance.
The better survival in Japan is unlikely to be attributable simply to
‘better’ treatment as, among those Hong Kong patients detected
within the Milan Criteria, the latter actually survived longer than
the Japanese cohort and by all other measures of survival in early-
stage disease according to treatment there were no significant
differences.
The progressive improvement in median survival between 1980
(when surveillance was initiated) and 2013 (from o3 months to
the current figure of470 months) in the Japanese cohort has been
replicated across Japan (Ikai et al, 2010). This observation cannot,
in itself, be taken as evidence for the benefit of surveillance since
there have, over the same period, been major advances in both
diagnosis and management. For example, we cannot be entirely
confident of the diagnosis of small HCCs in the early stages of the
study, before internationally agreed diagnostic criteria were
established. However, most small tumours did come to resection
and were thus histologically confirmed. Crucially however, whilst
in Hong Kong the survival has increased from 3 months (Shiu et al,
1990) to 17.8 months, in Japan the improvement (over the same
time period) has been to 52 months (30 months after adjusting for
lead-time bias). Furthermore, the parallel stage-shift to earlier
disease (as assessed by the JIS system) supports the contention that
survival improvement was, at least in part, attributable to
surveillance. In both Hong Kong and Japan, patients with chronic
HCV survived longer than those with HBV, suggesting that the
high incidence of HCV infection might contribute to the
better survival in Japan compared with Hong Kong. A direct
comparison, however, reveals that within each aetiology, Japanese
patients consistently survived longer. Interestingly, in both JapanT
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Table 4. Multivariable Cox regression analysis
_t
Haz.
ratio s.e Z P4z
95% Conf.
interval
Japan
Vascular invasion
No Ref.
Yes 2.815 0.397 7.34 o0.0001 2.136 3.71
Albumin 0.91 0.008  11.16 o0.0001 0.895 0.925
Log 10 AFP 1.279 0.047 6.75 o0.0001 1.191 1.373
Age 1.034 0.005 6.25 o0.0001 1.023 1.045
Tumour type
Solitary Ref.
Multifocal 1.605 0.153 4.97 o0.0001 1.332 1.935
Tumour size 1.05 0.008 6.22 o0.0001 1.034 1.067
Log 10 bilirubin 2.226 0.407 4.38 o0.0001 1.556 3.186
Gender
Female Ref.
Male 1.519 0.152 4.18 o0.0001 1.249 1.849
Hong Kong, China
Vascular invasion
No Ref.
Yes 2.501 0.186 12.35 o0.0001 2.162 2.892
Log 10 bilirubin 2.625 0.263 9.65 o0.0001 2.158 3.194
Tumour size 1.069 0.007 9.64 o0.0001 1.054 1.083
Albumin 0.949 0.006  8.76 o0.0001 0.938 0.96
Log 10 AFP 1.177 0.027 7.2 o0.0001 1.126 1.231
Tumour type
Solitary Ref.
Multifocal 1.566 0.106 6.64 o0.0001 1.372 1.788
Age 1.008 0.003 2.62 0.009 1.002 1.013
Abbreviations: AFP¼ a-fetoprotein; Ref.¼ reference.
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and Hong Kong, irrespective of how the HCC cases were detected,
those with HBV had clinical features characteristic of more
advanced disease.
However, there are significant limitations to our study. Crucial
issues such as cost effectiveness, and any harm inflicted by a
surveillance programme such as the consequence of false-positive
results, have not been considered. Furthermore, any benefit of
surveillance suggested here is not necessarily transferable to a
Western setting. Obesity is increasingly recognised as an
aetiological factor for HCC development in the West and this will
decrease the sensitivity of US examination, whereas US is likely to
be a more effective surveillance tool in the slimmer Japanese
population (Zaman, 2013). In Japan, patients at risk are a well-
informed population committed to surveillance and this may not
be the case in the West where compliance may be poor, especially
among those with alcoholic cirrhosis. Furthermore, only patients in
whom the presence of a risk factor for HCC is known (e.g., chronic
viral hepatitis) will enter a surveillance programme. In Hong Kong,
HCC was often the first manifestation of chronic hepatitis B
infection, whereas in Japan the population had already been
offered screening for the presence of chronic HBV or HCV. There
is abundant evidence from the United States that management
strategies developed and implemented in specialist centres are not
always replicated in the primary care setting and that the overall
percentage of patients with cirrhosis actually undergoing effective
surveillance is very low (El-Serag and Davila, 2010; Dalton-
Fitzgerald et al, 2014; Joshi et al, 2014). The multiple barriers that
inhibit translation of the potential benefits of surveillance into an
effective program at the population level have been clearly
described by Singal and El-Serag (2015).
Although a prospective randomised controlled trial (RCT) to
assess the impact of surveillance would be ideal, it is now
recognised that this approach is not practical (Poustchi et al, 2011;
McCaughan, 2013; Kansagara et al, 2014; Singal et al, 2014;
Sherman, 2014a, b); all other, non-RCT-based approaches have
significant limitations. Nonetheless, in the absence of an RCT, our
data when combined with the time trends shown here, and reports
from the whole of Japan (Toyoda et al, 2006a) and other parts of
Asia (Yeh et al, 2014), lend strong support for the beneficial impact
of surveillance on HCC mortality.
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